Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB

Ilyas Okur; Fatih Ezgu; Roberto Giugliani; Nicole Muschol; Anja Koehn; Hernan Amartino; Paul Harmatz; Maria J. de Castro Lopez; Maria Luz Couce; Shuan Pei Lin; Spyros Batzios; Maureen Cleary; Martha Solano; Heidi Peters; Joy Lee; Igor Nestrasil; Adam J. Shaywitz; Stephen M. Maricich; Bernice Kuca; Joseph Kovalchin; Eric Zanelli

doi:10.1016/j.jpeds.2022.06.005

Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB

Ilyas Okur, Fatih Ezgu, Roberto Giugliani, Nicole Muschol, Anja Koehn, Hernan Amartino, Paul Harmatz, Maria J. de Castro Lopez, Maria Luz Couce, Shuan Pei Lin, Spyros Batzios, Maureen Cleary, Martha Solano, Heidi Peters, Joy Lee, Igor Nestrasil, Adam J. Shaywitz, Stephen M. Maricich, Bernice Kuca, Joseph KovalchinEric Zanelli

Pediatrics - Neuropsychology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Objective: To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB. Study design: Sixty-five children with a confirmed diagnosis of MPS IIIB were enrolled into 1 of 2 natural history studies and followed for up to 4 years. Cognitive and adaptive behavior functions were analyzed in all subjects, and volumetric magnetic resonance imaging analysis of liver, spleen, and brain, as well as levels of heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE), were measured in a subset of subjects. Results: The majority of subjects with MPS IIIB achieved an apex on both cognition and adaptive behavior age equivalent scales between age 3 and 6 years. Development quotients for both cognition and adaptive behavior follow a linear trajectory by which subjects reach a nadir with a score <25 for an age equivalent of 24 months by age 8 years on average and by 13.5 years at the latest. All tested subjects (n = 22) had HS and HS-NRE levels above the normal range in cerebrospinal fluid and plasma, along with signs of hepatomegaly. Subjects lost an average of 26 mL of brain volume (−2.7%) over 48 weeks, owing entirely to a loss of cortical gray matter (32 mL; −6.5%). Conclusions: MPS IIIB exists along a continuum based on cognitive decline and cortical gray matter atrophy. Although a few individuals with MPS IIIB have an attenuated phenotype, the majority follow predicted trajectories for both cognition and adaptive behavior. Trial registration: ClinicalTrials.gov identifiers NCT02493998, NCT03227042, and NCT02754076.

Original language	English (US)
Pages (from-to)	50-58.e2
Journal	Journal of Pediatrics
Volume	249
DOIs	https://doi.org/10.1016/j.jpeds.2022.06.005
State	Published - Oct 2022

Bibliographical note

Funding Information:
These studies were funded by Allievex Corporation . B.K., J.K. and E.Z are employees of Allievex Corporation, and S.M.M. is a former employee of Allievex Corporation. The other authors declare no conflicts of interest.

Publisher Copyright:
© 2022 The Author(s)

Keywords

Sanfilippo syndrome Type III
adaptive behavior
cognition
natural history
organ MRI

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Access

10.1016/j.jpeds.2022.06.005

OpenUrl availability

Full text

Cite this

Okur, I., Ezgu, F., Giugliani, R., Muschol, N., Koehn, A., Amartino, H., Harmatz, P., de Castro Lopez, M. J., Couce, M. L., Lin, S. P., Batzios, S., Cleary, M., Solano, M., Peters, H., Lee, J., Nestrasil, I., Shaywitz, A. J., Maricich, S. M., Kuca, B., ... Zanelli, E. (2022). Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB. Journal of Pediatrics, 249, 50-58.e2. https://doi.org/10.1016/j.jpeds.2022.06.005

Okur, I, Ezgu, F, Giugliani, R, Muschol, N, Koehn, A, Amartino, H, Harmatz, P, de Castro Lopez, MJ, Couce, ML, Lin, SP, Batzios, S, Cleary, M, Solano, M, Peters, H, Lee, J, Nestrasil, I, Shaywitz, AJ, Maricich, SM, Kuca, B, Kovalchin, J & Zanelli, E 2022, 'Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB', Journal of Pediatrics, vol. 249, pp. 50-58.e2. https://doi.org/10.1016/j.jpeds.2022.06.005

@article{82c0c651e809438a93af1463ea07a2f7,

title = "Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB",

abstract = "Objective: To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB. Study design: Sixty-five children with a confirmed diagnosis of MPS IIIB were enrolled into 1 of 2 natural history studies and followed for up to 4 years. Cognitive and adaptive behavior functions were analyzed in all subjects, and volumetric magnetic resonance imaging analysis of liver, spleen, and brain, as well as levels of heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE), were measured in a subset of subjects. Results: The majority of subjects with MPS IIIB achieved an apex on both cognition and adaptive behavior age equivalent scales between age 3 and 6 years. Development quotients for both cognition and adaptive behavior follow a linear trajectory by which subjects reach a nadir with a score <25 for an age equivalent of 24 months by age 8 years on average and by 13.5 years at the latest. All tested subjects (n = 22) had HS and HS-NRE levels above the normal range in cerebrospinal fluid and plasma, along with signs of hepatomegaly. Subjects lost an average of 26 mL of brain volume (−2.7%) over 48 weeks, owing entirely to a loss of cortical gray matter (32 mL; −6.5%). Conclusions: MPS IIIB exists along a continuum based on cognitive decline and cortical gray matter atrophy. Although a few individuals with MPS IIIB have an attenuated phenotype, the majority follow predicted trajectories for both cognition and adaptive behavior. Trial registration: ClinicalTrials.gov identifiers NCT02493998, NCT03227042, and NCT02754076.",

keywords = "Sanfilippo syndrome Type III, adaptive behavior, cognition, natural history, organ MRI",

author = "Ilyas Okur and Fatih Ezgu and Roberto Giugliani and Nicole Muschol and Anja Koehn and Hernan Amartino and Paul Harmatz and {de Castro Lopez}, {Maria J.} and Couce, {Maria Luz} and Lin, {Shuan Pei} and Spyros Batzios and Maureen Cleary and Martha Solano and Heidi Peters and Joy Lee and Igor Nestrasil and Shaywitz, {Adam J.} and Maricich, {Stephen M.} and Bernice Kuca and Joseph Kovalchin and Eric Zanelli",

note = "Funding Information: These studies were funded by Allievex Corporation . B.K., J.K. and E.Z are employees of Allievex Corporation, and S.M.M. is a former employee of Allievex Corporation. The other authors declare no conflicts of interest. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = oct,

doi = "10.1016/j.jpeds.2022.06.005",

language = "English (US)",

volume = "249",

pages = "50--58.e2",

journal = "Journal of Pediatrics",

issn = "0022-3476",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB

AU - Okur, Ilyas

AU - Ezgu, Fatih

AU - Giugliani, Roberto

AU - Muschol, Nicole

AU - Koehn, Anja

AU - Amartino, Hernan

AU - Harmatz, Paul

AU - de Castro Lopez, Maria J.

AU - Couce, Maria Luz

AU - Lin, Shuan Pei

AU - Batzios, Spyros

AU - Cleary, Maureen

AU - Solano, Martha

AU - Peters, Heidi

AU - Lee, Joy

AU - Nestrasil, Igor

AU - Shaywitz, Adam J.

AU - Maricich, Stephen M.

AU - Kuca, Bernice

AU - Kovalchin, Joseph

AU - Zanelli, Eric

N1 - Funding Information: These studies were funded by Allievex Corporation . B.K., J.K. and E.Z are employees of Allievex Corporation, and S.M.M. is a former employee of Allievex Corporation. The other authors declare no conflicts of interest. Publisher Copyright: © 2022 The Author(s)

PY - 2022/10

Y1 - 2022/10

N2 - Objective: To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB. Study design: Sixty-five children with a confirmed diagnosis of MPS IIIB were enrolled into 1 of 2 natural history studies and followed for up to 4 years. Cognitive and adaptive behavior functions were analyzed in all subjects, and volumetric magnetic resonance imaging analysis of liver, spleen, and brain, as well as levels of heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE), were measured in a subset of subjects. Results: The majority of subjects with MPS IIIB achieved an apex on both cognition and adaptive behavior age equivalent scales between age 3 and 6 years. Development quotients for both cognition and adaptive behavior follow a linear trajectory by which subjects reach a nadir with a score <25 for an age equivalent of 24 months by age 8 years on average and by 13.5 years at the latest. All tested subjects (n = 22) had HS and HS-NRE levels above the normal range in cerebrospinal fluid and plasma, along with signs of hepatomegaly. Subjects lost an average of 26 mL of brain volume (−2.7%) over 48 weeks, owing entirely to a loss of cortical gray matter (32 mL; −6.5%). Conclusions: MPS IIIB exists along a continuum based on cognitive decline and cortical gray matter atrophy. Although a few individuals with MPS IIIB have an attenuated phenotype, the majority follow predicted trajectories for both cognition and adaptive behavior. Trial registration: ClinicalTrials.gov identifiers NCT02493998, NCT03227042, and NCT02754076.

AB - Objective: To characterize the longitudinal natural history of disease progression in pediatric subjects affected with mucopolysaccharidosis (MPS) IIIB. Study design: Sixty-five children with a confirmed diagnosis of MPS IIIB were enrolled into 1 of 2 natural history studies and followed for up to 4 years. Cognitive and adaptive behavior functions were analyzed in all subjects, and volumetric magnetic resonance imaging analysis of liver, spleen, and brain, as well as levels of heparan sulfate (HS) and heparan sulfate nonreducing ends (HS-NRE), were measured in a subset of subjects. Results: The majority of subjects with MPS IIIB achieved an apex on both cognition and adaptive behavior age equivalent scales between age 3 and 6 years. Development quotients for both cognition and adaptive behavior follow a linear trajectory by which subjects reach a nadir with a score <25 for an age equivalent of 24 months by age 8 years on average and by 13.5 years at the latest. All tested subjects (n = 22) had HS and HS-NRE levels above the normal range in cerebrospinal fluid and plasma, along with signs of hepatomegaly. Subjects lost an average of 26 mL of brain volume (−2.7%) over 48 weeks, owing entirely to a loss of cortical gray matter (32 mL; −6.5%). Conclusions: MPS IIIB exists along a continuum based on cognitive decline and cortical gray matter atrophy. Although a few individuals with MPS IIIB have an attenuated phenotype, the majority follow predicted trajectories for both cognition and adaptive behavior. Trial registration: ClinicalTrials.gov identifiers NCT02493998, NCT03227042, and NCT02754076.

KW - Sanfilippo syndrome Type III

KW - adaptive behavior

KW - cognition

KW - natural history

KW - organ MRI

UR - http://www.scopus.com/inward/record.url?scp=85134783967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85134783967&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2022.06.005

DO - 10.1016/j.jpeds.2022.06.005

M3 - Article

C2 - 35709957

AN - SCOPUS:85134783967

SN - 0022-3476

VL - 249

SP - 50-58.e2

JO - Journal of Pediatrics

JF - Journal of Pediatrics

ER -

Longitudinal Natural History of Pediatric Subjects Affected with Mucopolysaccharidosis IIIB

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this